Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

Better than I expected. Improved quarter that would have been much better without a large rise in admin and corporate costs. Rise maybe explained in commentary notes in perhaps preparation of expensive regulatory for new product approvals and preparation for increased manufacturing to meet anticipated demand. Not sure if they have set up any new offices within South east Asia which would also have added to Corp costs.
Did note the big hint in comments that they are receiving “intense market interest “ in their newly released spirosonic air device for post covid home lung monitoring .
solid improving quarter that would have been considerably better without the high admin and corporate cost is my take. Cash receipts improving year on year with growing products coming to market. Next 6-12 months is the key .